Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety
Therapeutic Advances in Gastroenterology
Published online on February 10, 2026
Abstract
Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Background:Vedolizumab is a gut-selective, anti-α4β7integrin antibody treatment for ulcerative colitis (UC) and Crohn’s disease (CD).Objectives:Long-term vedolizumab treatment persistence and safety were evaluated in patients who completed GEMINI LTS (...
Background:Vedolizumab is a gut-selective, anti-α4β7integrin antibody treatment for ulcerative colitis (UC) and Crohn’s disease (CD).Objectives:Long-term vedolizumab treatment persistence and safety were evaluated in patients who completed GEMINI LTS (...